Donate

Publication Details

Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm
Chronic myeloid leukaemia (CML) TKIs and TFR. A guide for patients

Chronic myeloid leukaemia (CML) TKIs and TFR. A guide for patients (September 2018)

This booklet is written for patients with Philadelphiachromosome-positive (Ph+) CML. It explains what tyrokinase inhibitors are and how they work. It covers imatinib, nilotinib, dasatinib, bosutinib, ponatinib, including how they are given and possible side-effects.

Author(s)
Leukaemia Care
Place of publication
Worcester
Publisher
Leukaemia Care
Date of publication
September 2018
Supplier
www.leukaemiacare.org.uk/
Subject(s)
Leukaemias, Philadelphia chromosome positive CML, Tyrosine kinase inhibitors, Imatinib, Nilotinib, Dasatinib, Bosutinib, Ponatinib
Format
Booklet
Language
English
Download this resource
Download this resource
Back to results
Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm
Donate

About this site

Macmillan sites

Right there with you

We're here to provide physical, financial and emotional support. So whatever cancer throws your way, we're right there with you. Contact us

Follow us

© Macmillan Cancer Support 2019 © Macmillan Cancer Support, registered charity in England and Wales (261017), Scotland (SC039907) and the Isle of Man (604). Also operating in Northern Ireland. A company limited by guarantee, registered in England and Wales company number 2400969. Isle of Man company number 4694F. Registered office: 89 Albert Embankment, London SE1 7UQ. VAT no: 668265007